Company Overview and News

18
TG Therapeutics At EHA 2018: Investors Unimpressed - Time To Get Focused

13m seekingalpha
June 15th: the market was unimpressed by myelofibrosis and long-term safety readouts for umbralisib, likely because myelofibrosis is a small indication and we already knew that umbralisib has excellent safety.
TGTX

18
TG Therapeutics and Novimmune Forge $185M Agreement

1h biospace
TG Therapeutics and NovImmune SA struck a collaborative deal worth up to $185 million on the development and commercialization of a treatment for hematologic B-cell malignancies, such as non-Hodgkin’s Lymphoma and chronic lymphocytic leukemia.
TGTX

121
TGTX / TG Therapeutics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-18 fintel.io
TG Therapeutics, Inc. (NASDAQ:TGTX) has 133 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 41,045,824 shares. Largest shareholders include venBio Select Advisor LLC, FMR LLC / Fidelity, BlackRock Inc., State Street Corp, Vanguard Group Inc, RA Capital Management, LLC, Franklin Resources Inc, Bridger Management, Llc, BlackRock Fund Advisors, and BlackRock Institutional Trust Company, N.
STT PRTO BLK STT.PRC TGTX STT.PRE STT.PRD STT.PRG BEN GALPW GALE GALEW

18
TGTX / TG Therapeutics, Inc. / LFB Biotechnologies S.A.S.U. - SC 13D AMENDMENT NO. 2 (Activist Investment)

2018-06-18 sec.gov
SC 13D Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGTX

23
TGTX / TG Therapeutics, Inc. / LFB Biotechnologies S.A.S.U. - SC 13D AMENDMENT NO. 2 (Activist Investment)

2018-06-18 sec.gov
SC 13D Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGTX

18
TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab in Patients with Multiple Sclerosis at the 4th Congress of the European Academy of Neurology

2018-06-18 globenewswire
NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced updated results from the Phase 2 multicenter trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS). The data is being presented today at the 4th Congress of the European Academy of Neurology in Lisbon, Portugal, via an oral session titled “MS and related Disorders 2”, at 17:00 CET.
TGTX

18
TG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy at the 23rd Congress of the European Hematology Association (EHA)

2018-06-18 globenewswire
NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced an oral presentation of clinical data from its ongoing Phase 2 study evaluating umbralisib (TGR-1202), the Company’s PI3K delta inhibitor, in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy. Data from this trial were presented over the weekend during an oral session at the 23rd Congress of the European Hematology Association (EHA).
TGTX

166
MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright

2018-06-16 zacks
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism. AdvaMed, the medical device industry’s lobbying group, which strongly advocated for this relief, noted that the tax repeal will provide a huge impetus to the companies to channelize their turnovers into strategic consolidations, research and developments and also help in creating new job opportunities.
IFK TGTX NXTM SRXTY BAX OSUR 1302 BSX SYK INSY CAH SRX SXMDF IFX ISRG HSIC 0165 MDT EGRX FTV JNJ SRDX ABMD ROSA

23
TGTX / TG Therapeutics, Inc. 8-K (Current Report)

2018-06-13 sec.gov
Blueprint UNITED STATES
TGTX

96
7 Killer Stock Picks for the Second Half of 2018

2018-06-08 investorplace
The first half of 2018 hasn’t been easy. And there’s no promise that the second half of the year will be any easier. Far from it. Market commentators still can’t decide whether the bull market is here to stay or whether a bear market is lurking just around the corner.
TGTX LOXO MS.PRE MS.PRF MS.PRG MS.PRA LOGM MS.PRI GM.WS.A MS.PRK GM.WS.B DG GM.WS.C TSLA GM MS GM.WSB DAL DE

18
TG Therapeutics, Inc. to Present at the Jefferies 2018 Global Healthcare Conference

2018-06-05 globenewswire
NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference, being held at the Grand Hyatt Hotel, in New York City. The presentation is scheduled to take place on Thursday, June 7, 2018 at 10:30am ET.
TGTX

TGTX : TG Therapeutics Stock Analysis and Research Report

2017-11-09 - Asif

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, TG Therapeutics is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors, BET (Bromodomain an...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 88322Q108